|Healthcare Review: Heat Biologics, Sarepta Therapeutics, Auxilium Pharmaceuticals, Galena Biopharma, BioLineRx|
|By Staff and Wire Reports|
|Thursday, 21 August 2014 14:04|
U.S. stocks rose Thursday, carrying the S&P 500 index to an intraday record high, after several upbeat economic reports. The S&P 500 added four points, or 0.2%, to 1991 after hitting a record intraday high of 1992.68 earlier in the session. The Dow Jones Industrial Average rose 67 points, or 0.4%, to 17045. The Nasdaq Composite Index slipped two points, or 0.1%, to 4524. Benchmarks climbed higher shortly after Thursday's opening bell and coasted into the early afternoon. Stocks have rallied over the past week, with the S&P 500 on pace for its fourth straight gain.
Shares of thinly-traded nano cap Heat Biologics ($HTBX) jump on a 10x surge in volume (~1.1M) on no news.Shares have languished since last July's IPO at $10. Prices peaked at $15.29 on October 3 and bottomed at $3.60 on August 7.The company's lead product candidate is the cancer immunotherapeutic HS-110 (viagenpumatucel-L) for non-small cell lung cancer.
Sarepta Therapeutics (SRPT) establishes a multi-year multi-product partnership with Colorado-based Flagship Biosciences LLC to develop automated tissue-based quantitative tests related to muscular dystrophy that will support the advancement of Sarepta's product pipeline.
Galena Biopharma ($GALE) appoints Mark W. Schwartz, Ph.D., as President & CEO effective immediately replacing Mark J. Ahn, Ph.D. Previously, Dr. Schwartz was the company's EVP and COO.
Auxilium Pharmaceuticals (NASDAQ:AUXL) announces the results from a Phase 2a clinical trial evaluating the safety and efficacy of injections of collagenase clostridium histolyticum (CCH) for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Three doses (low-0.06mg; mid-0.48mg; high-0.84mg) of CCH showed an improvement in the appearance of cellulite as measured by investigator- and patient-generated scores on the Global Aesthetic Improvement Scale (GAIS).
The USPTO issues a Notice of Allowance to BioLineRx (NASDAQ:BLRX) covering the use of its polymer, BL-7010, for the prevention or decreasing of gluten's deleterious side effects on the gastrointestinal mucosa. The patent, when issued, will be in effect until 2026.